Showing 661 - 680 results of 693 for search '"Parkinson's disease"', query time: 0.06s Refine Results
  1. 661

    Neuroborreliosis with encephalitis: a broad spectrum of clinical manifestations by Dominica Hudasch, Franz Felix Konen, Nora Möhn, Lea Grote-Levi, Ulrich Wurster, Gabriel Welte, Josef Conzen, Nima Mahmoudi, Thomas Skripuletz, Philipp Schwenkenbecher

    Published 2025-02-01
    “…Clinical manifestations ranged from cognitive impairments resembling primary dementia to movement disorders mimicking Parkinson's disease, tremor, and epileptic seizures. In 5/7 patients (71%) they occurred between August to September. …”
    Get full text
    Article
  2. 662

    A Comparison of Pain between Parkinson’s Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey by He-Yang You, Lei Wu, Hai-Ting Yang, Chen Yang, Xiao-Ling Ding

    Published 2019-01-01
    “…This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients. …”
    Get full text
    Article
  3. 663

    Basal ganglia components have distinct computational roles in decision-making dynamics under conflict and uncertainty. by Nadja R Ging-Jehli, James F Cavanagh, Minkyu Ahn, David J Segar, Wael F Asaad, Michael J Frank

    Published 2025-01-01
    “…We collected intracranial recordings from patients diagnosed with either Parkinson's disease (PD) (n = 14) or dystonia (n = 3) in the subthalamic nucleus (STN), globus pallidus internus (GPi), and globus pallidus externus (GPe) during their performance of a novel perceptual discrimination task in which we independently manipulated uncertainty and conflict. …”
    Get full text
    Article
  4. 664

    Parkinson’s disease and other movement disorders in the context of the SARS-COV-2 pandemic by R. Kaladytė Lokominienė

    Published 2020-06-01
    “…Amantadine and memantine are presumed to have some anti-SARS-CoV-2 potential but this assumption should be confirmed in clinical trials. International Parkinson Disease and Movement Disorders Society has published recommendations and priorities for patients with Parkinson’s disease and other movement disorders during the COVID-19 pandemic which state that all measures of social distancing currently in place for the general population almost globally must be strictly and carefully practiced, direct consultations must be held in exceptional cases (e.g., for adjusting or checking deep brain stimulation programming, battery failure, levodopa duodenal pump treatments, botulinum toxin therapy), and patients should be encouraged to use sports equipment available at home and /or play virtual reality games. …”
    Get full text
    Article
  5. 665

    Mechanisms and Consequences of Dopamine Depletion-Induced Attenuation of the Spinophilin/Neurofilament Medium Interaction by Andrew C. Hiday, Michael C. Edler, Asma B. Salek, Cameron W. Morris, Morrent Thang, Tyler J. Rentz, Kristie L. Rose, Lisa M. Jones, Anthony J. Baucum

    Published 2017-01-01
    “…Signaling changes that occur in the striatum following the loss of dopamine neurons in the Parkinson disease (PD) are poorly understood. While increases in the activity of kinases and decreases in the activity of phosphatases have been observed, the specific consequences of these changes are less well understood. …”
    Get full text
    Article
  6. 666

    Factors associated with early-onset androgenetic alopecia: A scoping review. by Li-Ping Liu, Mary Adumo Wariboko, Xiao Hu, Zi-Han Wang, Qian Wu, Yu-Mei Li

    Published 2024-01-01
    “…Comorbidities investigated included MetS, cardiovascular disease, insulin resistance, dyslipidemia, and Parkinson's disease. Men with early-onset AGA may have reduced treatment efficacy with drug like rosuvastatin, metformin or lisinopril for dyslipidemia, prediabetes, or hypertension. …”
    Get full text
    Article
  7. 667

    Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk by Zeyu Wang, Zixiao Yin, Guangyong Sun, Dong Zhang, Jianguo Zhang

    Published 2025-02-01
    “…A systematic investigation of the genetic relationship between lipid metabolism abnormalities and ND, namely, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), is lacking. …”
    Get full text
    Article
  8. 668

    The “Gender Factor” in Wearing-Off among Patients with Parkinson’s Disease: A Post Hoc Analysis of DEEP Study by Delia Colombo, Giovanni Abbruzzese, Angelo Antonini, Paolo Barone, Gilberto Bellia, Flavia Franconi, Lucia Simoni, Mahmood Attar, Emanuela Zagni, Shalom Haggiag, Fabrizio Stocchi

    Published 2015-01-01
    “…The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). …”
    Get full text
    Article
  9. 669

    Routine Multimodal Antiemesis Including Low-Dose Perphenazine in an Ambulatory Surgery Unit of a University Hospital: A 10-Year History by Brian A. Williams, Michael L. Kentor, Susan J. Skledar, Steven L. Orebaugh, Manuel C. Vallejo

    Published 2007-01-01
    “…As a single-dose component of multimodal antiemetic prophylaxis therapy, we believe that this track record of anecdotal safety in adults who meet certain criteria (age 14–70, no less than 45 kg, no history of extrapyramidal reactions or of Parkinson disease, and no Class III antidysrhythmic coadministered for coexisting disease) constitutes a sufficient patient safety basis for formal prospective study. …”
    Get full text
    Article
  10. 670

    Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design by Michael S Okun, Peter Schmidt, David W Brodell, Nicole T Stanford, Charles E Jacobson

    Published 2012-12-01
    “…Objective Sinemet, a combination drug containing carbidopa and levodopa is considered the gold standard therapy for the treatment of Parkinson's disease (PD). When approved by the Food and Drug Administration (FDA) in 1988, a maximum daily dosage limit of 800 mg (eight tablets) of the 25/100 carbidopa/levodopa formulation was introduced. …”
    Get full text
    Article
  11. 671

    Can Table Tennis Extend Lifespan? An Analysis of Its Impact on Physical Health, Brain Function, and Mental Well-being by Patrycja Marta, Agata Ossolińska, Filip Huzarski, Gabriela Ferfecka, Klaudia Pawełek, Lucyna Stolarska, Magdalena Rosa-Bończak, Natalia Morawiecka, Olivier Carlton, Weronika Kłosowicz

    Published 2025-02-01
    “…The sport stimulates cognitive functions such as reflexes, anticipation, and memory, with studies confirming its positive effects on individuals with Parkinson's disease, dementia, or mild cognitive impairment. …”
    Get full text
    Article
  12. 672

    The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils by Lee Josephson PhD, Nancy Stratman MS, YuTing Liu MS, Fang Qian MS, Steven H. Liang PhD, Neil Vasdev PhD, Shil Patel PhD

    Published 2018-09-01
    “…Development of an α-synuclein (α-Syn) positron emission tomography agent for the diagnosis and evaluation of Parkinson disease therapy is a key goal of neurodegenerative disease research. …”
    Get full text
    Article
  13. 673

    Efficacy of transcranial magnetic stimulation in anorexia nervosa: a systematic review and meta-analysis by Amir Reza Bahadori, Parisa Javadnia, Sanaz Bordbar, Rasa Zafari, Tina Taherkhani, Afshan Davari, Abbas Tafakhori, Sajad Shafiee, Sara Ranji

    Published 2025-01-01
    “…Abstract Purpose Transcranial magnetic stimulation (TMS) has emerged as a promising treatment for various neuropsychiatric conditions, including depression, obsessive–compulsive disorder, and Parkinson's disease. Recent research has focused on evaluating its effectiveness in treating patients with anorexia nervosa (AN). …”
    Get full text
    Article
  14. 674

    Protective effects of wogonin in the treatment of central nervous system and degenerative diseases by Qingan Fu, Qingyun Yu, Hongdan Luo, Zhekang Liu, Xiaowei Ma, Huijian Wang, Zhijuan Cheng

    Published 2025-02-01
    “…Moreover, wogonin shows promise in treating neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease by promoting autophagy and reducing neuroinflammation. …”
    Get full text
    Article
  15. 675

    The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases by Rojin Sarallah, Shima Jahani, Alireza Soltani Khaboushan, Amir Kian Moaveni, Maryam Amiri, Masoumeh Majidi Zolbin

    Published 2025-02-01
    “…Neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS), are characterized by progressive neuronal loss and cognitive impairment (CI). …”
    Get full text
    Article
  16. 676

    Nerve‐Inspired Optical Waveguide Stretchable Sensor Fusing Wireless Transmission and AI Enabling Smart Tele‐Healthcare by Tianliang Li, Qian'ao Wang, Zichun Cao, Jianglin Zhu, Nian Wang, Run Li, Wei Meng, Quan Liu, Shifan Yu, Xinqin Liao, Aiguo Song, Yuegang Tan, Zude Zhou

    Published 2025-01-01
    “…Abstract Flexible strain monitoring of hand and joint muscle movement is recognized as an effective method for the diagnosis and rehabilitation of neurological diseases such as stroke and Parkinson's disease. However, balancing high sensitivity and large strain, improving wearing comfort, and solving the separation of diagnosis and treatment are important challenges for further building tele‐healthcare systems. …”
    Get full text
    Article
  17. 677
  18. 678

    Clinical Decision Support Using Speech Signal Analysis: Systematic Scoping Review of Neurological Disorders by Upeka De Silva, Samaneh Madanian, Sharon Olsen, John Michael Templeton, Christian Poellabauer, Sandra L Schneider, Ajit Narayanan, Rahmina Rubaiat

    Published 2025-01-01
    “…In the included studies, Parkinson disease, Alzheimer disease, and cognitive disorders were the most frequently investigated conditions. …”
    Get full text
    Article
  19. 679

    USP14 is crucial for proteostasis regulation and α-synuclein degradation in human SH-SY5Y dopaminergic cells by Vignesh Srinivasan, Rabah Soliymani, Larisa Ivanova, Ove Eriksson, Nina Peitsaro, Maciej Lalowski, Mati Karelson, Dan Lindholm

    Published 2025-02-01
    “…Ubiquitin specific protease-14 (USP14) is critical for controlling proteostasis disturbed in human disorders, including Parkinson's disease (PD). Here we investigated USP14 in the regulation of α-synuclein (α-syn) degradation via the proteasome and autophagy. α-Syn and pS129 α-syn were elevated in USP14 gene-deleted SH-SY5Y dopaminergic cells with decreased proteasome activity. …”
    Get full text
    Article
  20. 680

    Research Progress of Nerve Mobilization in Basic and Clinical Rehabilitation by Shuo LUAN, Quanshou LING, Miaoshang ZENG, Anni LIN, Yingping JIANG

    Published 2019-06-01
    “…Despite of insufficient evidence, the NM is proved to be used in the prevention, assessment and treatment of neurological disorders, including stroke, traumatic brain injury and Parkinson's disease. Moreover, previous studies proved that peripheral mechanical loads applied to neural tissues could improve the central neural plasticity, and the improvements were observed in muscular tone, strength, body weight distribution, postural balance and other functional motor performances, which helped to attenuate the motor dysfunction of the upper and lower limbs. …”
    Get full text
    Article